Overview
ONC market data
Price History
ONC price chart
Valuation & Profitability
- P/E (TTM)
- 72.17 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.98 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.74 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 15.3% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $205.51 – $346.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $228.3K · P/B 8.68 · P/S 5.61.
Company news
JP Morgan Maintains Overweight on BeOne Medicines, Raises Price Target to $425Benzinga · Jul 23, 2026, 6:36 PM
BeOne Medicines Announces $300M Expansion Of Its Manufacturing And R&D Center In New Jersey; Total U.S. Manufacturing Investment Reaches $1B+Benzinga · Jul 23, 2026, 10:10 AM
Barclays Maintains Overweight on BeOne Medicines, Lowers Price Target to $403Benzinga · Jul 14, 2026, 11:02 AM
BeOne Medicine shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised its price target from $333 to $380.Benzinga · Jul 13, 2026, 11:38 AM
Jefferies Upgrades BeOne Medicines to Buy, Raises Price Target to $380Benzinga · Jul 13, 2026, 10:49 AM
RBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $451Benzinga · Jul 7, 2026, 4:15 PM
Truist Securities Maintains Buy on BeOne Medicines, Raises Price Target to $416Benzinga · Jul 7, 2026, 12:25 PM
Citizens Reiterates Market Outperform on BeOne Medicines, Maintains $396 Price TargetBenzinga · Jul 1, 2026, 1:50 PM
BeOne Medicines Advances Chemotherapy-Free Lymphoma StrategyBenzinga · Jun 30, 2026, 5:55 PM
BeOne Medicines To Present Large Phase 3 Dataset Showing Sustained Benefit With BRUKINSA After Nearly 6.5 Years Of Follow-UpBenzinga · Jun 11, 2026, 11:26 AM